Page 11 - Aurobindo Pharma

Aurobindo Pharma gets USFDA approval for drug used to sedate patients

Drug major Aurobindo Pharma said it has received final approval from the US health regulator for generic of Precedex injection, used for sedation of patients

Aurobindo Pharma completes sale of US subsidiary's Natrol to New Mountain

Drug firm Aurobindo Pharma said it has completed the sale of Natrol LLC, a wholly-owned unit of its US-based subsidiary, to private equity firm New Mountain Capital

Aurobindo Pharma expects to commercialise Covid-19 vaccine facility by May

Aurobindo Pharma expects to commercialise its Covid-19 vaccine manufacturing facility in Hyderabad by April-May next year, according to a top company official

Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico

The chart pattern and positioning of oscillators are pointing towards a sharp up move in Aurobindo Pharma in the near future

Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug

Pfizer Inc alleged that the drug makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent

Aurobindo, Zydus, Jubilant, others recall various products in US market

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

Aurobindo Pharma rallies 6% as Q2 net profit rises 26% YoY to Rs 805.65 cr

The company's consolidated total revenue from operations stood at Rs 6,483.44 crore.

Aurobindo Pharma reports 26% increase in Q2 net profit at Rs 805 crore

The company said it received final approval for 10 ANDAs (abbreviated new drug applications) from USFDA

Bull run continues; Sensex up 316 pts to end at 43,594, Nifty nears 12,750

All that happened in the markets today.

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

Top headlines: Aurobindo Pharma to sell Natrol; Navratri drives car sales

From Aurobindo Pharma's plans to sell US-based Natrol to Kishore Biyani looking for mutual settlement, here are top headlines this morning

Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore

Aurobindo's stock reacted positively to the news, going up in morning trade but later settled flat at Rs 784.65 on the BSE

Divestment of US subsidiary to leave Aurobindo Pharma cash positive

Divestment of the US subsidiary is at good valuations and will help attain net cash positive status

Aurobindo Pharma tumbles over 3% after USFDA warning letter to subsidiary

Shares of Aurobindo Pharma on Thursday closed over 3 per cent lower after the company's step-down subsidiary received a warning letter from the US health regulator for its unit in New Jersey, US.

Aurobindo Pharma gets USFDA nod for pain treatment injection Acetaminophen

Drug firm Aurobindo Pharma on Thursday said it has received final approval from the US health regulator for its generic Acetaminophen injection, used in the treatment of pain in adult and paediatric patients. The company has received the approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen injection, 1,000 mg/ 100 mL single-dose vial, Aurobindo Pharma said in a BSE filing. The product will be launched in December 2020, it added. It is a generic version of Mallinckrodt's Ofirmev injection. According to IQVIA data, the approved product has an estimated market size of USD 339 million for the twelve months ending August 2020, Aurobindo Pharma said. Acetaminophen Injection is indicated for the treatment of mild to moderate pain in adult and paediatric patients 2 years and older. It is also set to treat moderate to severe pain with adjunctive opioid analgesics in adult and paediatric patients 2 years and older, and reduction of fever, the ...

Aurobindo Pharma arm's New Jersey unit gets warning letter from USFDA

Drug firm Aurobindo Pharma said its step-down subsidiary has received a warning letter from the US health regulator for its unit in New Jersey, US

Aurobindo Pharma declines 6% on USFDA warning letter for Dayton facility

The company said it would engage with the regulator and would try to resolve the issue at the earliest

Stock recommendation by Prabhudas Lilladher: Buy Hindalco, Aurobindo Pharma

The RSI indicator for Hindalco Industries has recently indicated a decent rise to imply strength

Stock calls by Nilesh Jain of Anand Rathi: Buy Bharat Forge, L&T Infotech

The stock of Bharat Forge has formed a strong base and has started making a higher top and higher bottom formation on the daily chart

Aurobindo Pharma: Multiple growth triggers to improve Street sentiment

Rebound in injectable sales, multiple product launches, strong European outlook and reduction in net debt are key earning triggers